More recently, Lee et al. also reported that DPP-4 inhibitor users have a 50% increased risk of pancreatic cancer incidence (aHR 1.50, 95%CI: 1.02–2.20) among newly diagnosed T2DM patients. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.